title: Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hanover, Germany. Electronic address: Maasoumy.benjamin@mh-hannover.de.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Maasoumy
authors.affiliation: Department of Medicine 1, University Hospital Frankfurt, Frankfurt am Main, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Vermehren
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hanover, Germany.
authors.forename: Heiner
authors.initials: H
authors.lastname: Wedemeyer
authors.affiliation: Department of Medicine 1, University Hospital Frankfurt, Frankfurt am Main, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Sarrazin
mesh_terms: D000998:Antiviral Agents; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C; D019698:Hepatitis C, Chronic; D006801:Humans; D007700:Kinetics; D012313:RNA; D012367:RNA, Viral; D012254:Ribavirin; D000069474:Sofosbuvir; D000072230:Sustained Virologic Response
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin; D012313:RNA; D000069474:Sofosbuvir